Skip to content

Food and Drug Recall.org

The Latest Food & Drug Recall and Safety News

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes

December 16, 2015Drug Recalls & Safety Notices, Drug Safety Information Podcasts, Food & Drug Recalls, Food Safety Newsadmin

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Post navigation

← Trader Joe’s Issues Voluntary Recall of Triple Ginger Brew FDA approves wearable defibrillator for children at risk for sudden cardiac arrest →
Proudly powered by WordPress